生产企业：Climb Bio, Inc. (global rights outside Greater China), Beijing Mabworks Biotech (Mabworks) (Greater China partner)
CLYM116 is an anti-APRIL monoclonal antibody in clinical development for IgA nephropathy (IgAN). It employs a pH-dependent 'sweeper' mechanism that promotes lysosomal degradation of APRIL and recycles the antibody, potentially enabling less-frequent dosing. Phase 1 studies in healthy volunteers have demonstrated a favorable safety profile with no serious adverse events at single doses up to 320 mg.
CLYM116 is an anti-APRIL monoclonal antibody in clinical development for IgA nephropathy (IgAN). It employs a pH-dependent 'sweeper' mechanism that promotes lysosomal degradation of APRIL and recycles the antibody, potentially enabling less-frequent dosing. Phase 1 studies in healthy volunteers have demonstrated a favorable safety profile with no serious adverse events at single doses up to 320 mg.
CLYM116 is a clinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic B-cell activity in autoimmune diseases. CLYM116 employs a novel pH-dependent bind-and-release 'sweeper' mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for rapid, deep, and durable inhibition of APRIL with a favorable safety profile and less frequent dosing.
CLYM116 is being developed for the treatment of IgA nephropathy (IgAN). Mabworks, Climb Bio's partner in Greater China, expects to initiate dosing in IgAN patients in the Phase 2 portion of its ongoing study in Q3 2026. CLYM116 may also have broader utility across other B-cell mediated diseases where APRIL plays a critical role.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
